Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R)

Abstract

Background Virologic failure to approved combinations of direct antiviral agents (DAA) in patients with chronic hepatitis C virus (HCV) infection is rare. Mostly it involves difficult to treat patients with advanced liver disease and prior interferon-experience. Before approval of VOX/VEL/SOF, a restricted number of patients received rescue treatment, and the choice of DAA combinations for re-treatment were selected on an individual basis. In the present analysis, patient characteristics and rescue-regimens after virologic failure mainly based on first generation DAAs are described.

Patients and methods Data were obtained from the German Hepatitis C-Registry (DHC-R), which is a national multicenter real-world cohort currently including about 16 500 patients recruited by more than 250 centers. The present analysis is based on 6683 patients who initiated a DAA therapy and for whom follow-up data (per-protocol analysis) were available.

Results Among the patients, 188 (2.8 %) experienced a virologic relapse. Compared to SVR-patients, relapse patients were significantly more often male (77.7 % versus 56.9 %, respectively, p < 0.001), showed cirrhosis significantly more (48.4 % versus 28.1 %, respectively, p < 0.001) and a prior interferon-containing therapy (46.3 % versus 39.0 %, respectively, p = 0.049). The majority of patients who relapsed were infected with genotype 1 (47.4 %) followed by genotype 3 (29.8 %), and 95 relapse patients started DAA re-treatment. Characteristics of patients with rescue-treatment are similar to these of patients with relapse after initial DAA treatment. Thirty-one of 39 patients with complete follow-up data achieved SVR (79.5 %), and 8 patients had a relapse again (20.5 %). Patients who received rescue treatment including a new DAA class according to guidelines, except patients who received VOX/VEL/SOF, showed higher SVR rates than the entire group (21/25, 84 %). All patients who received VOX/VEL/SOF achieved SVR (n = 4, 100 %).

Conclusions Patients with failure with DAA combination therapies are a difficult but urgent to treat population with the frequent presence of cirrhosis and prior treatment failure with interferon-based therapies. Rescue therapy with inclusion of a new DAA class leads to high SVR rates, but multiple targeted therapy with VOX/VEL/SOF seems to be most effective.

Zusammenfassung

Hintergrund Virologisches Versagen nach einer zugelassenen Kombinationstherapie aus direkt antiviral wirkenden Medikamenten (DAA) bei Patienten mit chronischer Hepatitis-C-Virus(HCV)-Infektion ist sehr selten. Zumeist handelt es sich, aufgrund von fortgeschrittener Lebererkrankung und vorangegangenen interferonbasierten Therapien, um schwierig zu behandelnde Patienten. Vor Zulassung von VOX/VEL/SOF erhielt eine geringe Zahl von Patienten eine Rescue-Therapie, und die Wahl der DAA-Kombination zur Re-Therapie unterlag individuellen Entscheidungskriterien. Die vorliegende Arbeit beschreibt Charakteristika und Rescue-Therapien, überwiegend basierend auf DAAs der ersten Generation, bei Patienten nach virologischem Versagen.

Patienten und Methoden Die Daten entstammen dem Deutschen Hepatitis C-Register (DHC-R). Dieses ist eine nationale, multizentrische, Real-World-Kohorte, die derzeit über 16 500 Patienten aus über 250 Zentren einschließt. Die aktuelle Analyse basiert auf 6683 Patienten mit initialer DAA-Therapie und kompletten Follow-up-Daten (Per-Protocol(PP)-Analyse).

Ergebnisse 188 Patienten (2,8 %) aus der PP-Population hatten einen virologischen Relapse. Die Relapse-Patienten waren verglichen zur SVR-Population signifikant häufiger männlich (77,7 % versus 56,9 %, p < 0,001), hatten signifikant häufiger eine Zirrhose (48,4 % versus 28,1 %, p < 0,001) und eine interferonbasierte Vortherapie (46,3 % versus 39,0 %, p = 0,049). Die meisten Patienten mit virologischem Versagen waren mit Genotyp 1 (57,4 %) gefolgt von Genotyp 3 (29,8 %) infiziert. 95 der Relapse-Patienten erhielten eine DAA-Re-Therapie. Die Charakteristika von Patienten mit Rescue-Therapie sind vergleichbar mit denen von Patienten mit Relapse nach initialer DAA-Therapie. 31 von 39 Patienten mit kompletten Follow-up-Daten erreichten SVR (79,5 %) und 8 Patienten erlitten einen erneuten Relapse (20,5 %). Patienten, die eine den Leitlinien entsprechende Rescue-Therapie mit einer neuen DAA-Klasse erhalten haben, ausgenommen VOX/VEL/SOF, zeigten höhere SVR-Raten als die Gesamtgruppe (21/25, 84 %). Alle Patienten, die VOX/VEL/SOF erhielten, erreichten einen SVR (n = 4, 100 %).

Schlussfolgerung Versager nach DAA-Kombinationstherapie entsprechen einer schwierig und zugleich dringlich zu behandelnden Patientengruppe mit häufigem Vorliegen einer Zirrhose und Versagen einer interferonbasierten Vortherapie. Rescue-Therapie mit einer neuen DAA-Klasse führt zu hohen SVR-Raten, eine Multi-Target-Therapie mit VOX/VEL/SOF scheint am effektivsten zu sein.

Key words

direct acting antivirals - HCV - relapse - rescue-treatment - SVR 12 - patient characteristics - real world setting

Schlüsselwörter

Direkt antiviral wirkende Substanzen - HCV - Relaps - Rescue-Therapie - SVR 12 - Patienten-Charakteristika - Real-world Bedingungen

• References

• 1 Afdhal N, Zeuzem S, Kwo P. et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-1898
• 2 Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016; 64: 486-504
• 3 Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon–free regimens. Gastroenterology 2016; 151: 70-86
• 4 Calleja JL, Crespo J, Rincon D. et al. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: results from a Spanish real-world cohort. J Hepatol 2017; 66: 1138-1148
• 5 Cornberg M, Petersen J, Schober A. et al. Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2017; 45: 688-700
• 6 Tacke F, Gunther R, Buggisch P. et al. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int 2017; 37: 205-211
• 7 Honer Zu Siederdissen C, Buggisch P, Boker K. et al. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterol J 2018; 6: 213-224
• 8 Buggisch P, Vermehren J, Mauss S. et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol 2017; DOI: 10.1016/j.jhep.2017.11.009.
• 9 European Association for the Study of the Liver. European Association for the Study of the L. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69: 461-511
• 10 Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010; 138: 447-462
• 11 Abdel-Moneim A, Aboud A, Abdel-Gabbar M. et al. A sofosbuvir-based quadruple regimen is highly effective in HCV type 4-infected Egyptian patients with DAA treatment failure. J Hepatol 2018; 68: 1313-1315
• 12 de Ledinghen V, Laforest C, Hezode C. et al. Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: The ANRS HC34 REVENGE study. Clin Infect Dis 2018; 66: 1013-1018
• 13 Bourliere M, Gordon SC, Flamm SL. et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 2017; 376: 2134-2146
• 14 Bischoff J, Mauss S, Cordes C. et al. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy?. HIV Med 2018; 19: 299-307
• 15 Christensen S, Buggisch P, Mauss S. et al. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: still a concern in clinical practice?. Addiction 2018; 113: 868-882
• 16 Welzel TM, Hinrichsen H, Sarrazin C. et al. Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat 2017; 24: 840-849
• 17 Huppe D, Serfert Y, Buggisch P. et al. 4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R). Z Gastroenterol 2019; 57: 27-36
• 18 Sarrazin C, Berg T, Buggisch P. et al. S3 guideline hepatitis C addendum. Z Gastroenterol 2015; 53: 320-334
• 19 Sarrazin C, Berg T, Buggisch P. et al. Current recommendations for the treatment of chronic hepatitis C. Z Gastroenterol 2014; 52: 1185-1197
• 20 Sarrazin C, Berg T, Ross RS. et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2010; 48: 289-351
• 21 D’Ambrosio R, Pasulo L, Puoti M. et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol 2019; 70: 379-387
• 22 Laurain A, Metivier S, Haour G. et al. Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort. BMC Infect Dis 2019; 19: 300
• 23 Poordad F, Pol S, Asatryan A. et al. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology (Baltimore, Md) 2018; 67: 1253-1260
• 24 Wyles D, Weiland O, Yao B. et al. Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection. J Hepatol 2019; 70: 1019-1023
• 25 European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2016. J Hepatol 2017; 66: 153-194
• 26 Vermehren J, Park JS, Jacobson IM. et al. Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. J Hepatol 2018; 69: 1178-1187
• 27 Belen Perez A, Chueca N, Garcia-Deltoro M. et al. High efficacy of Resistance-guided retreatment of HCVpatients failing NS5A inhibitors in real world. J Hepatol 2019; DOI: 10.1016/j.jhep.2019.06.022.
• 28 Zarebska-Michaluk D, Buczynska I, Simon K. et al. Real world experience of chronic hepatitis C retreatment with genotype specific regimens in nonresponders to previous interferon-free therapy. Can J Gastroenterol Hepatol 2019; 2019: 4029541
• 29 Tam E, Luetkemeyer AF, Mantry PS. et al. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naive patients: findings from 2 randomized trials. Liver Int 2018; 38: 1010-1021
• 30 Gower E, Estes C, Blach S. et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014; 61: S45-S57
• 31 Berden FA, Aaldering BR, Groenewoud H. et al. Identification of the best direct-acting antiviral regimen for patients with hepatitis C virus genotype 3 infection: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 349-359
• 32 von Felden J, Vermehren J, Ingiliz P. et al. High efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2018; 47: 1288-1295
• 33 Osawa M, Imamura M, Teraoka Y. et al. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures. J Gastroenterol 2018; DOI: 10.1007/s00535-018-1520-9.